艾迪注射液联合DP化疗方案对NSCLC血清肿瘤标志物水平的影响

Effects of Aidi Injection Combined with DP Chemotherapy Regimen on Serum Tumor Markers in Patients with NSCLC

目的探讨艾迪注射液结合多西他赛+顺铂(DP)化疗对非小细胞肺癌(NSCLC)患者血清肿瘤标志物水平的影响。方法选取2020年10月至2022年10月在本院收治的96例NSCLC患者,使用随机数字表法将其分为艾迪联合DP组和DP组各48例,并比较两组的疗效、血清肿瘤标志物水平以及不良反应的差异。结果艾迪联合DP组有效率41.67%,明显高于DP组(22.92%)(P<0.05)。治疗后,艾迪联合DP组和DP组的CEA和CYFRA21-1水平均显著降低(P<0.05),而艾迪联合DP组的降低幅度显著低于DP组(P<0.05)。此外,两组不良反应发生率也存在显著差异(P<0.05)。结论艾迪注射剂和DP化疗的联合治疗对NSCLC疗效显著,有助于降低肿瘤标志物水平并减少不良反应发生率。

Objective To explore the effect of Aidi injection combined with docetaxel and cisplatin(DP)chemotherapy on serum tumor marker levels in non-small cell lung cancer(NSCLC)patients.Methods A total of 96 NSCLC patients admitted to our hospital from October 2020 to October 2022 were selected.They were randomly divided into two groups using a random number table method:the Aidi combined DP group and the DP group,with 48 cases in each group.The differences in efficacy,serum tumor marker levels,and adverse reactions between the two groups were compared.Results The effective rate of the combination of Aidi combined DP group was 41.67%,significantly higher than that of the DP group(22.92%)(P<0.05).After treatment,the CEA and CYFRA21-1 levels in both the Aidi combined DP group and DP group were significantly reduced(P<0.05),while the decrease in the Aidi combined DP group was significantly lower than that in the DP group(P<0.05).In addition,there was a significant difference in the incidence of adverse reactions between the two groups(P<0.05).Conclusion The combination therapy of Aidi injection and DP chemotherapy has a significant therapeutic effect on NSCLC,which helps to reduce tumor marker levels and reduce the incidence of adverse reactions.